G N Thalmann
Overview
Explore the profile of G N Thalmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dal Pra A, Ghadjar P, Ryu H, Proudfoot J, Hayoz S, Michalski J, et al.
Ann Oncol
. 2025 Feb;
PMID: 39986927
Background: The SAKK 09/10 trial randomized biochemically recurrent prostate cancer patients to salvage radiation 64 Gy versus 70 Gy, and the NRG/RTOG 0126 randomized intermediate-risk prostate cancer patients to definitive...
2.
Giudici N, Schoch A, Genitsch V, Rodriguez-Calero A, Thalmann G, Seiler R
Urol Oncol
. 2024 Jun;
42(10):333.e15-333.e20.
PMID: 38942714
Introduction: Similar to bladder cancer, about one third of upper tract urothelial carcinoma (UTUC) present variant histology (VH). We aim to evaluate the incidence, clinical characteristics and the impact on...
3.
Dal Pra A, Ghadjar P, Hayoz S, Liu V, Spratt D, Thompson D, et al.
Ann Oncol
. 2022 May;
33(9):950-958.
PMID: 35636621
Background: The Decipher genomic classifier (GC) has shown to independently prognosticate outcomes in prostate cancer. The objective of this study was to validate the GC in a randomized phase III...
4.
Horwich A, Babjuk M, Bellmunt J, Bruins H, de Reijke T, De Santis M, et al.
Ann Oncol
. 2019 Nov;
30(11):1697-1727.
PMID: 31740927
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary...
5.
Bosshard P, Thalmann G, Roth B
Urologe A
. 2019 Jan;
58(1):25-29.
PMID: 30649582
Traditionally, urothelial carcinoma of the upper urinary tract was a clear indication for radical nephroureterectomy with bladder cuff excision. It has been shown that in well-selected patients and depending on...
6.
Lyttwin B, Moltzahn F, Thalmann G
Urologe A
. 2017 Apr;
56(7):864-867.
PMID: 28405707
Testicular trauma is a rare emergency. While penetrating injuries need surgical revision, blunt injuries may be treated conservatively. However, in case of testicular rupture early surgical intervention increases the chance...
7.
Genitsch V, Zlobec I, Thalmann G, Fleischmann A
Prostate Cancer Prostatic Dis
. 2016 May;
19(3):242-7.
PMID: 27165976
Background: MUC1 is a membrane-bound glycoprotein that belongs to the mucin family. It is involved in cell adhesion and intracellular signaling. Aberrant expression of MUC1 has been observed in different...
8.
Gakis G, Morgan T, Daneshmand S, Keegan K, Todenhofer T, Mischinger J, et al.
Ann Oncol
. 2015 May;
26(8):1754-9.
PMID: 25969370
Background: To investigate the impact of perioperative chemo(radio)therapy in advanced primary urethral carcinoma (PUC). Patients And Methods: A series of 124 patients (86 men, 38 women) were diagnosed with and...
9.
Tschui J, Vassella E, Bandi N, Baumgartner U, Genitsch V, Rotzer D, et al.
Virchows Arch
. 2015 Mar;
466(6):703-10.
PMID: 25809292
Several (pre-) clinical trials are currently investigating the benefit of HER2-targeted therapy in urothelial bladder cancer (UBC). Patients with HER2 amplified UBC could potentially profit from these therapies. However, little...
10.
Vidal A, Thalmann G, Karamitopoulou-Diamantis E, Fey M, Studer U
Ann Oncol
. 2014 Nov;
26(2):374-7.
PMID: 25392157
Background: To report the long-term results of adjuvant treatment with one cycle of modified bleomycin, etoposide, and cisplatin (BEP) in patients with clinical stage I (CS I) nonseminomatous germ-cell tumors...